As of March 2, confirmed cases of COVID-19 now number more than 115 million around the world, including more than 29 million cases in the United States and more than 522,000 U.S. deaths. You can see a breakdown of coronavirus cases throughout the world and within the U.S. on the map and chart above.
Below you’ll find updates on the latest news about the coronavirus.
March 2 News Updates
Fauci Says Moderna & Pfizer Recipients Should Continue with Two-Dose Approach
Dr. Anthony Fauci shared on March 1 that he still believes the U.S. should continue to give two doses to people who receive the Moderna or Pfizer vaccines, The Washington Post reported. He said he understands the UK’s approach ith delaying second doses, but does not believe the U.S. should follow that example.
Fauci said: “There’s risks on either side… We’re telling people [two shots] is what you should do … and then we say, ‘Oops, we changed our mind’? I think that would be a messaging challenge, to say the least.”
Brazil Variant Might Be Able to Reinfect People
A new coronavirus variant in Brazil, called P.1, may be leading to reinfections, The New York Times reported. The variant is dominating the city of Manaus, partly due to being more contagious. However, experts are warning that this variant might lead to reinfection after mixing the variant with COVID-19 antibodies and finding the antibodies’ effectiveness dropped six-fold.
Laboratory experiments revealed that it might also weaken the protection from a Chinese vaccine used in Brazil. However, more research is needed before drawing conclusions.
Johnson & Johnson and Merck Will Work Together to Increase Vaccine Production
Merck and Johnson & Johnson, two companies that are historically competitors, will work together to increase vaccine production, CNN reported. President Joe Biden is expected to announce on March 2 that Merck will help J&J manufacture its vaccine.
France Authorizes AstraZeneca Vaccine for People Over 65
After initially declining to do so, France has now authorized the AstraZeneca-Oxford vaccine for people over the age of 65, The Local reported on March 2. The vaccine is now authorized for people ages 65 to 74 with underlying health conditions. France’s health authority revised its opinion on the vaccine, where it had originally only offered it to people ages 18 to 65 due to lack of clinical data.
10% of U.S. Adults Are Now Vaccinated for COVID-19
The CDC announced that 10% of U.S. adults have now been vaccinated for COVID-19, U.S. News & World Report shared. This adds up to more than 77 million administered doses and more than 96 million delivered.
Overweight People May Need a Larger Dose of the Pfizer Vaccine
Italy researchers have proposed that people with a higher BMI may need a larger dose of the Pfizer vaccine, Independent reported. The study looked at 158 females and 90 males, and saw that people with a higher BMI had a lower antibody response. Women and younger people also showed a higher antibody response. Researchers proposed that constant inflammation from being overweight might weaken immune responses. However, more studies are needed before a recommendation can be made.
More than 800 People in Colorado Have Caught COVID-19 Twice
The Colorado Department of Public Health and Environment (CDPHE) announced that there are 822 cases of reinfections in the state from August 20 to February 28, KKTV reported. To qualify, cases had to be separated by 90 days or more and include two positive molecular amplification tests. Labs need to genetical sequence both samples to confirm a reinfection.
CDC Launches VaccineFinder to Locate Vaccines Near You
The Centers for Disease Control and Prevention (CDC) launched a COVID-19 VaccineFinder tool that allows people in the United States to look for a novel coronavirus vaccine near them. To use the VaccineFinder, you can visit the VaccineFinder’s homepage here and click on “Find COVID-19 Vaccines.” The VaccineFinder only includes participating providers, so everyone may not be listed. Learn more in Heavy’s story here.
Additional Vaccine Updates
Pfizer Updates (mRNA vaccine):
The first dose of the two-dose Pfizer/BioNTech vaccine delivers about 90% protection after 21 days, The Guardian reported in February. Meanwhile, a peer-reviewed study of about 9,000 people by Sheba Medical Center and published in Lancet in February showed that the first Pfizer dose brings 85% efficacy in preventing symptomatic disease within 15 to 28 days of the shot, The Wall Street Journal reported in mid-February. The new study, however, looked at people who were younger and healthier, one author noted, and didn’t confirm how long protection lasts.
A real-world study in Israel of the Pfizer-BioNTech vaccine shows a 94% efficacy in symptomatic infection following two doses, Reuters reported. The efficacy was the same across all age groups and co-morbidities. The study looked at 1.2 million people, and the UK variant was dominant when the study was performed. Efficacy against the SA variant wasn’t part of the study.
Preliminary results in a preprint revealed that Pfizer’s vaccine reduces the viral load four-fold 12 to 28 days after the first dose, The Scientist reported. This study compared nearly 3,000 vaccinated people with unvaccinated people. You can read the preprint here.
Experts disagree on whether a second dose can be delayed or not. Professor Ugur Sahin, chief executive at BioNTech, told Sky News that up to six weeks between the first and second Pfizer dose should be fine, but not longer than that. In contrast, two Canadian researchers said in a New England Journal of Medicine letter that because the first dose has 92.6% efficacy, the second Pfizer dose can be delayed, CTV News reported.
The UK warned that people with serious allergic reactions to a vaccine, medicine, or food — or who have had near-fatal allergic reactions — shouldn’t get the COVID-19 Pfizer vaccine, AP News reported in early December.
Pfizer/BioNTech is working on boosters specifically against the new coronavirus variants, Newsweek reported in late January. If any variants show resistance to the current vaccine, Pfizer wants to be able to produce a booster “very, very quickly.” A February study at the University of Texas revealed that the Pfizer vaccine still provides substantial protection against the SA variant, The Guardian reported. The researchers did acknowledge limitations, including not having the full set of spike mutations in the test.
In late February, the FDA approved the Pfizer vaccine for normal freezer storage (temperatures of -25°C to -15°C) for up to two weeks, Time reported. This was in response to new data submitted by Pfizer-BioNTech regarding stability at those higher temperatures. In ultra-cold storage, the vaccine is approved for six months of storage.
One dose of the Pfizer vaccine can serve as a booster for people who already had the novel coronavirus, according to a research paper in Lancet, SciTechDaily reported.
Moderna Updates (mRNA vaccine):
Data released in mid-December shows that Moderna’s vaccine is highly protective, The New York Times reported. The vaccine had an efficacy of 94.1% in a trial with 30,000 participants. Side effects were not dangerous but were unpleasant, including fever, headache, and fatigue. During trials, Moderna (and CanSino) both stopped giving high doses for the second dose because of the side effects, StatNews reported. Moderna’s current vaccine uses a lower dose for the second dose.
Moderna announced on January 25 that individuals who got the Moderna COVID-19 vaccine are showing neutralizing antibody activity against the UK and South Africa variants too (B.1.1.7 and B.1.351.) A weaker response was observed for the South Africa variant (B.1.351), but Moderna noted that “neutralizing titer levels … are expected to be protective.” Moderna is advancing work on a variant booster dose against the South Africa strain.
A study of the Moderna vaccine from Emory University and the University of Texas Medical Branch in early February also indicates that it generated neutralizing antibodies against variants, News Medical reported. The study still must undergo peer review.
Moderna is working on a booster vaccine targeted to the South Africa strain, Independent reported in late February. The booster is called mRNA-1273.351. Moderna is looking into different ways to deliver the booster, including as a third dose, as the second in two sets, or mixed with the current vaccine.
The Oxford-AstraZeneca vaccine is about 62% effective in people who got two full doses, BBC reported in late November. Another trial showed about 90% efficacy in 3,000 people who got a half-dose first and then a full dose the second time rather. The Oxford vaccine is made from an adenovirus that was modified to help human cells create the spike protein so the immune system can recognize it, Nature reported. This is similar to how Johnson & Johnson’s vaccine works.
AstraZeneca is also testing a component of Russia’s Sputnik V vaccine in its own clinical trials, according to a press release. The Russian vaccine uses two inoculations based on two different human adenovirus vectors.
AstraZeneca’s vaccine is facing some issues, however. The EU authorized the vaccine, but Germany, Poland, Sweden, Italy, and France are all advising against its use in older residents due to lack of data so far. Ireland stated that mRNA vaccines are preferable for older age groups. Several states in Germany have requested that unused AstraZeneca vaccines be allowed to be given to younger people, The Straits Times reported on March 1.
Switzerland’s medical regulator, SwissMedic, has said that it will not authorize the AstraZeneca vaccine, Irish Times reported.
Meanwhile, South Africa paused its AstraZeneca/Oxford vaccine rollout in early February after an analysis revealed the vaccine only provides minimal protection against the B.1.351 South Africa variant, StatNews reported. A small study revealed that the AstraZeneca vaccine may only provide 10% protection against mild to moderate infections of the SA variant, while they had wanted 60% or higher, The Guardian reported.
The AstraZeneca vaccine gives mild side effects like a temperature or a headache, Reuters reported. But French health authorities recommended staggering the shot among health care workers so operations aren’t disrupted. The French medicines safety agency said that the side effects are “known” and described in trials, but should still be surveilled for intensity.
Health Canada regulators approved the Oxford-AstraZeneca vaccine, which showed an efficacy of 62%, CBC reported in late February. Canada secured 22 million doses, most of which will arrive from April to September. Dr. Supriya Sharma, Health Canada’s chief medical adviser, said that AstraZeneca is less effective than Pfizer and Moderna, but is better than not getting any vaccine. Sharma said that all the vaccines are good at preventing hospitalizations and decreasing deaths.
Russia’s Sputnik Updates
Russia’s Sputnik vaccine is reported to be 91.6% effective against symptomatic COVID-19 and 100% effective against moderate and severe cases, CNN reported in early February. This is reported in interim Phase 3 trials and published in The Lancet. People over age 60 showed a 91.8% efficacy. Serious reactions were rare, and most side effects included mild-flu like symptoms, pain at the injection, and low energy. The analysis hasn’t reviewed asymptomatic cases, transmission, or how long protection lasts.
Russians who receive the Sputnik V coronavirus vaccine are being asked not to drink alcohol for two months after, the New York Post reported. This is the amount of time they said it takes the vaccine to be effective and alcohol can be a strain on the body’s immune response, the experts said.
In mid-February, the first 100,000 doses of the Sputnik vaccine arrived in Venezuela, Yahoo News reported. On February 23, AP reported that Mexico received its first shipment of the Sputnik vaccine: 200,000 doses.
Novavax announced that in its Phase 1 vaccine trial for NVX-CoV2373, antibodies were induced in 100% of participants, The Motley Fool reported. The vaccine had mild side effects, typically worse with the second dose. On November 9, it was granted fast-track designation by the FDA and is in late-phase clinical development. This is not an mRNA vaccine, ScienceMag reported. Instead, Novavax is using a baculovirus to insert a gene for the spike protein, harvesting the spike proteins and using that in an adjuvant.
In mid-February, FT reported that Novavax was about to finish its U.S. trial of the vaccine in record time, having enrolled 30,000 participants since beginning the trial in late December. A UK trial of the two-shot vaccine found it 85.6% effective against B.1.1.7 and 95.6% effective against the original variant.
Inovio is working on a vaccine called the INO-4800 DNA vaccine. Inovio announced positive results from two Phase I clinical trials in early July. The Phase 1 trial was expanded to include older participants in June and July. This is a nucleic-based vaccine that will be stable at room temperature for more than a year and doesn’t need to be frozen.
On January 4, Inovio said it expected to begin a late-stage study of its vaccine in the U.S. in the second quarter of 2021 after finishing mid-stage trials in March, Reuters reported. The vaccine has three mid-stage trials, one in the U.S., one in China with Advaccinek, and one in South Korea. The U.S. Phase III trial had been delayed as the FDA requested more information on the delivery device.
On February 12, Inovio shares traded higher, Seeking Alpha reported. Analyst Hartaj Singh believed Inovio’s vaccine showed promise, noting: “We believe the overall DNA platform by INO should not be overlooked.”
Johnson & Johnson Updates
Johnson & Johnson applied for an emergency use authorization for its vaccine, Stat News reported. If approved, the vaccine might begin being used in early March or even late February. The supply will be limited at first. Johnson & Johnson reported 66% efficacy at preventing moderate to severe COVID-19. It was 72% effective in the United States and 57% effective in South Africa, perhaps pointing to a vulnerability to variants. No one who got the vaccine was hospitalized or died.
Johnson & Johnson’s subsidiary Janssen applied to the EMA for conditional authorization for its vaccine in mid-February.
Data related to Johnson & Johnson’s vaccine shows 66% overall effectiveness: 57% in South Africa (rising to 64% after about a month), 66% in Latin America, and 72% in the United States, CNBC reported. The vaccine group reported no deaths, while the placebo group reported seven deaths. People ages 60 and older with comorbidities had a lower efficacy rate of about 42.3%. You can read the 62-page FDA briefing document from Johnson & Johnson here.
On February 12, EMA began a rolling review of CureVac’s vaccine, CVnCoV, EMA reported. CureVac is conducting clinical trials on safety, immune response, and effectiveness. CureVac utilizes the mRNA vaccination method.
On February 25, CureVac announced that preliminary animal trials showed it was effective against UK and SA variants, Reuters reported.
Sanofi and GlaxoSmithKline Updates
Sanofi and GlaxoSmithKline vaccine early trials were disappointing, The New York Times reported in mid-December. The vaccines didn’t produce a good immune response in older participants, although they did in people under 50.